Nicholas Marko
机构: LewisGale Medical Center
每年引用次数
引用次数
引用: 2,086
H-指数: 25
I10-指数 : 41
出版物: 84
The Molecular Biology of Diffuse Low-Grade Gliomas
Nicholas F. Marko , Robert J. Weil
Diffuse Low-Grade Gliomas in Adults 99 -115
2013
A case for reclassifying infiltrating gliomas in adults.
Nicholas F. Marko , Robert J. Weil
Journal of Neuro-oncology 109 ( 3) 587 -591
3
2012
Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature
Daniel Lubelski , Kalil G. Abdullah , Robert J. Weil , Nicholas F. Marko
Journal of Neuro-oncology 115 ( 3) 317 -322
47
2013
Does metabolic radiolabeling stimulate the stress response? Gene expression profiling reveals differential cellular responses to internal beta vs. external gamma radiation
Nicholas F. Marko , Paul B. Dieffenbach , Gai Yan , Susan Ceryak
The FASEB Journal 17 ( 11) 1470 -1486
32
2003
Why is there a lack of consensus on molecular subgroups of glioblastoma? Understanding the nature of biological and statistical variability in glioblastoma expression data.
Nicholas F. Marko , John Quackenbush , Robert J. Weil
PLOS ONE 6 ( 7)
16
2011
Stereotactic radiosurgical treatment of brain metastases to the choroid plexus.
Vitaly Siomin , Jennifer L. Lin , Nicholas F. Marko , Gene H. Barnett
International Journal of Radiation Oncology Biology Physics 80 ( 4) 1134 -1142
12
2011
Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Nicholas F. Marko , Richard A. Prayson , Gene H. Barnett , Robert J. Weil
Genomics 95 ( 1) 16 -24
18
2010
Genomic expression patterns distinguish long-term from short-term glioblastoma survivors: A preliminary feasibility study
Nicholas F. Marko , Steven A. Toms , Gene H. Barnett , Robert Weil
Genomics 91 ( 5) 395 -406
41
2008
Introduction to the Genomics special edition on clinical and translational genomics.
Nicholas F. Marko
Genomics 102 ( 2) 73
1
2013
Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to Surgery
Nicholas F. Marko , Robert J. Weil , Jason L. Schroeder , Frederick F. Lang
Journal of Clinical Oncology 32 ( 8) 774 -782
298
2014
Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer.
Zhiyuan Xu , Nicholas F. Marko , Lilyana Angelov , Gene H. Barnett
Cancer 118 ( 5) 1323 -1333
4
2012
Hyperosmolar Therapy for Intracranial Hypertension: Time to Dispel Antiquated Myths
Nicholas F. Marko
American Journal of Respiratory and Critical Care Medicine 185 ( 5) 467 -468
10
2012
The molecular biology of WHO grade II gliomas.
Nicholas F. Marko , Robert J. Weil
Neurosurgical Focus 34 ( 2)
16
2013
Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly.
Nicholas F. Marko , Emily LaSota , Amir H. Hamrahian , Robert J. Weil
Journal of Neurosurgery 117 ( 3) 522 -538
36
2012
The case for a comparative, value-based alternative to the patient-centered outcomes research model for comparative effectiveness research.
Nicholas F. Marko , Robert J. Weil
Neurosurgical Focus 33 ( 1)
1
2012
Comparative effectiveness research in neurosurgery
Nicholas F. Marko , Robert J. Weil
Neurosurgical Focus 33 ( 1)
1
2012
Role of Gamma Knife surgery in patients with 5 or more brain metastases.
Alireza Mohammad Mohammadi , Pablo F. Recinos , Gene H. Barnett , Robert J. Weil
Journal of Neurosurgery 117 5 -12
30
2012
Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres
Richard S. Polin , Nicholas F. Marko , Matthew D. Ammerman , Mark E. Shaffrey
Journal of Neurosurgery 102 ( 2) 276 -283
35
2005
Hyperosmolar Therapy for Intracranial Hypertension
Andrew Torre-Healy , Nicholas F. Marko , Robert J. Weil
Neurocritical Care 17 ( 1) 117 -130
40
2012
Management of incidental pituitary tumors
Nicholas F. Marko , Robert J. Weil
Oncology Reviews 5 ( 4) 233 -239
1
2011